# Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

> **NCT03634800** · PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 6 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Nivolumab 240mg
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT03634800
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-23
- **Primary completion:** 2020-01-09
- **Final completion:** 2020-01-16
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Lack of patient accruals.
- **Last updated:** 2021-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634800, "Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03634800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*